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Abstract
Although advanced inter-atrial block (aIAB) is an established electrocardiographic phenotype, its 
prevalence, incidence, and prognostic significance in the general population are unclear. We 
examined the prevalence, incidence, and prognostic significance of aIAB in 14,625 (mean 
age=54±5.8 years; 26% black; 55% female) participants from the Atherosclerosis Risk In 
Communities (ARIC) study. aIAB was detected from digital electrocardiograms recorded during 4 
study visits (1987–1989, 1990–1992, 1993–1995, and 1996–1998). Risk factors for the 
development of aIAB were examined using multivariable Poisson regression models with robust 
variance estimates. Cox regression was used to compute hazard ratios (HR) and 95% confidence 
intervals (CI) for the association between aIAB, as a time-dependent variable, and atrial 
fibrillation (AF). AF was ascertained from study electrocardiogram data, hospital discharge 
records, and death certificates thorough 2010. A total of 69 (0.5%) participants had aIAB at 
baseline and 193 (1.3%) developed aIAB during follow-up. The incidence rate for aIAB was 2.27 
(95%CI=1.97, 2.61) per 1000 person-years. Risk factors for aIAB development included age, male 
sex, white race, antihypertensive medication use, low-density lipoprotein cholesterol, body mass 
index, and systolic blood pressure. In a Cox regression analysis adjusted for socio-demographics, 
cardiovascular risk factors, and potential confounders, aIAB was associated with an increased risk 
for AF (HR=3.09, 95%CI=2.51, 3.79). In conclusion, aIAB is not uncommon in the general 
population. Risk factors for developing aIAB are similar to those for AF and the presence of aIAB 
is associated with an increased risk for AF.
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INTRODUCTION
Advanced inter-atrial block (aIAB) exists when a delay of conduction occurs over the 
Bachmann bundle.1 It manifests on the 12-lead electrocardiogram (ECG) as a prolonged P-
wave with biphasic morphology (±) in the inferior leads. Although aIAB is an established 
electrocardiographic phenotype, its prevalence, incidence, and prognostic significance in the 
general population are unclear. Previous reports from patient-based populations have shown 
that aIAB is associated with an increased risk for paroxysmal supraventricular 
tachyarrhythmias.2,3 The presence of aIAB also was shown to be an independent predictor 
of new-onset atrial fibrillation (AF) in patients with heart failure and among patients with 
atrial flutter.4,5 Additionally, aIAB has been associated with a higher risk of AF recurrence 
after pharmacological cardioversion to normal sinus rhythm.6 To date, the association 
between aIAB and AF has not been examined in prospective population-based studies. 
Therefore, the purpose of this analysis was to examine the prevalence and incidence of aIAB 
as well as the association between aIAB and AF in the Atherosclerosis Risk In Communities 
(ARIC) study, a community-based prospective cohort study.
METHODS
The ARIC study prospectively enrolled 15,792 community-dwelling men and women 
between 45 and 64 years of age. Four field centers across the United States (Washington 
County, MD; Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN) recruited 
participants between 1987 and 1989. Participants returned for 4 follow-up examinations 
(1990–1992, 1993–1995, 1996–1998, and 2011–2013), and continue to be followed via 
annual telephone calls to ascertain study end points. Endpoints are further ascertained from 
examination of lists of hospital discharges that include any cardiovascular diagnoses from 
hospitals in the study communities. The study was approved by the institutional review 
boards at all participating universities and all participants provided written informed consent 
at the time of study enrollment.
For this analysis, we excluded participants with AF (n=37), those with missing baseline 
covariates (n=783), and participants with missing follow-up data (n=384). Additionally, the 
few ARIC participants with race other than black or white were excluded, including the 
small number of black participants from Washington County and Minneapolis.
Digital 12-lead ECGs were obtained at baseline and at subsequent follow-up examinations 
using MAC PC ECG machines (Marquette Electronics, Milwaukee, WI). All ECGs were 
inspected for technical errors and adequate quality at the Epidemiology Coordinating and 
Research Centre at the University of Alberta (Edmonton, Alberta, Canada) during the initial 
phases of the study and at the Epidemiological Cardiology Research Center at the Wake 
Forest School of Medicine (Winston-Salem, North Carolina, USA) during later phases. 
aIAB manifests on the 12-lead ECG with a P-wave duration ≥120 ms and biphasic (positive 
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negative) morphology in leads II, III and AVF.1 Prevalent aIAB was identified using baseline 
ECG data and incident aIAB cases were detected during the first 3 follow-up study visits 
(1990–1992, 1993–1995, and 1996–1998).
Cases of AF were identified from study visit ECGs, review of hospital discharge diagnoses, 
and death certificates.7 A cardiologist visually confirmed all AF cases automatically 
detected from the study ECGs.8 Information on hospitalizations during follow-up was 
obtained from annual follow-up calls and surveillance of local hospitals, with hospital 
discharge diagnosis codes collected by trained abstractors. AF during follow-up was defined 
by International Classification of Diseases, 9th Revision codes 427.31 or 427.32. AF cases 
detected in the same hospitalization as open cardiac surgery were not included since these 
were considered transient.9
Age, sex, and race were self-reported. Tobacco use was defined as current or former 
cigarette smoking. Diabetes was defined as a fasting glucose level ≥126 mg/dL (or non-
fasting glucose ≥200 mg/dL), a physician diagnosis of diabetes, or the use of diabetes 
medications. Systolic blood pressure was obtained from each participant using 
sphygmomanometers to measure 3 readings in the upright position after 5 minutes of rest. 
The average of the last 2 blood pressure measurements was used as the final reading. 
Antihypertensive medication use was self-reported. Body mass index was defined as the 
weight in kilograms divided by the square of the height in meters. Low-density lipoprotein 
cholesterol levels were calculated indirectly using cholesterol values assayed from serum 
samples obtained at the baseline study visit. Prevalent heart failure was defined as present if 
participants reported taking heart failure medications or if participants met all 3 of the 
Gothenburg criteria.10 Prevalent coronary heart disease was defined by self-reported history 
of physician-diagnosed myocardial infarction, coronary artery bypass surgery, coronary 
angioplasty, or electrocardiographic evidence of myocardial infarction.
Categorical variables were reported as frequency and percentage while continuous variables 
were recorded as mean ± standard deviation. Baseline characteristics were examined by 
stratifying participants by the presence of the following: prevalent aIAB, incident aIAB, and 
no aIAB. Differences between groups were tested using the chi-square test for categorical 
variables and the analysis of variance procedure for continuous variables.
Kaplan-Meier estimates were used to compute the cumulative incidence of aIAB. Prevalent 
aIAB cases were excluded in the analysis to examine incident aIAB. Follow-up time was 
defined as the time between the baseline visit until aIAB development, loss to follow-up, 
death, or the end of study visit 4 (1996–1998). To examine risk factors for aIAB 
development, we examined the association between baseline characteristics, obtained from 
study visit 1, and incident aIAB using multivariable Poisson regression with robust variance 
estimates to compute relative risk (RR) and 95% confidence intervals (CI).11 Models were 
adjusted as follows: Model 1 adjusted for demographics (age, sex, and race) and Model 2 
adjusted for variables in Model 1 plus body mass index, systolic blood pressure, use of 
blood pressure lowering medication, smoking, diabetes, low-density lipoprotein cholesterol, 
coronary heart disease, and heart failure.
O’Neal et al. Page 3
Am J Cardiol. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Kaplan-Meier estimates also were used to examine the cumulative incidence of AF by the 
presence of aIAB as a time-dependent variable. The first 3 follow-up study visits were used 
to identify more aIAB cases due to the limited number of cases present in the baseline study 
visit. Follow-up was defined as the time between aIAB detection until AF development, loss 
to follow-up, death or end of follow-up (December 31, 2010). The period between the 
baseline visit and aIAB diagnosis was considered as non-aIAB follow-up. Cox regression 
was used to compute hazard ratios (HR) and 95% CIs for the association between aIAB as a 
time-dependent variable and AF. Multivariable models were constructed with baseline 
characteristics, obtained from study visit 1, as follows: Model 1 adjusted for age, sex, and 
race; Model 2 adjusted for Model 1 covariates plus body mass index, systolic blood 
pressure, use of blood pressure lowering medication, smoking, diabetes, low-density 
lipoprotein cholesterol, coronary heart disease, and heart failure. Statistical significance was 
defined as p <0.05. SAS version 9.4 (Cary, NC) was used for all analyses.
RESULTS
A total of 14,625 (mean age=54±5.8 years; 26% black; 55% female) participants were 
included in the final analysis. A total of 69 (0.5%) participants had aIAB at baseline and 193 
(1.3%) cases of aIAB were detected on subsequent study ECGs (mean follow-up=5.9 years). 
Baseline characteristics stratified by prevalent aIAB, incident aIAB, and no aIAB are shown 
in Table 1. Participants with aIAB were more likely to be older, male, and white, and to have 
diabetes, coronary heart disease, and heart failure compared with those without aIAB. They 
also were more likely to smoke, to take antihypertensive medications, and to have higher 
values for body mass index and systolic blood pressure.
The crude incidence rate for aIAB was 2.27 (95%CI=1.97, 2.61) cases per 1000 person-
years. Table 2 shows the unadjusted and adjusted risk factors for aIAB development. As 
shown, age, male sex, white race, antihypertensive medication use, low-density lipoprotein 
cholesterol, body mass index, and systolic blood pressure were significantly associated with 
aIAB development.
Over a mean follow-up of 18.6 years, a total of 1,929 (13%) AF cases were identified. A 
higher incidence rate (per 1000 person-years) of AF was observed among those with aIAB 
(29.8, 95%CI=24.5, 36.3) compared with those without IAB (6.8, 95%CI=6.5, 7.1). The 
unadjusted cumulative incidence of AF by aIAB is shown in Figure 1. After adjustment for 
demographics and potential confounders, aIAB was associated with an increased risk of AF 
(Table 3).
DISCUSSION
In this analysis from ARIC, we have shown that aIAB is not uncommon in the general 
population and identified several risk factors associated with its development. Several of the 
risk factors identified are known to be associated with AF.12,13 Additionally, we have shown 
that aIAB is associated with the development of AF.
The prevalence of aIAB is reported to be around ~1% in patients with valvular heart disease 
and several small studies have reported a higher prevalence of aIAB in persons with heart 
O’Neal et al. Page 4
Am J Cardiol. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
failure, AF, and typical atrial flutter.4–6,14 The higher prevalence in the aforementioned 
studies likely is due to the populations examined (e.g., those with structural heart disease). In 
contrast, we observed a lower prevalence in the ARIC study, as this community-based 
population is not limited to participants with cardiovascular disease. Interestingly, coronary 
heart disease and heart failure were not associated with an increased risk of aIAB 
development. However, it is probable that our study was underpowered to detect associations 
between these risk factors and aIAB.
The association between aIAB and atrial arrhythmias has been reported. A study of 16 
patients with aIAB and 22 controls showed that patients with aIAB and retrograde activation 
of the left atrium have a much higher incidence of paroxysmal supraventricular 
tachyarrhythmias.2,3 aIAB also is associated with an increased risk for new-onset AF in 
patients with severely reduced ejection fraction who undergo cardiac resynchronization 
therapy and among patients with typical atrial flutter who receive cavotricuspid isthmus 
ablation.4,5 Additionally, aIAB has been associated with an increased risk of AF recurrence 
after successful pharmacologic cardioversion to normal sinus rhythm.6 Our findings extend 
prior literature by linking aIAB with AF in a population-based cohort not limited to persons 
who are high risk for AF development (e.g., heart failure). Given that several risk factors 
identified for aIAB development also are associated with AF, both conditions possibly are 
linked through shared comorbid conditions.12,13
The ECG pattern of aIAB is due to blockade of the electrical impulse in the upper and 
middle part of the inter-atrial septum in the Bachman bundle.1 The left atrium is then 
depolarized by retrograde activation via muscle connections near the coronary sinus. This 
abnormal conduction disrupts normal electrical activation and predisposes to the 
development of arrhythmias by modifying atrial refractory periods.15 Additionally, abnormal 
activation leads to premature beats that serve as inciting events for supraventricular 
arrhythmias. These abnormal properties often are observed among persons with risk factors 
for myocardial fibrosis and abnormal cardiac remodeling (e.g., advanced age, hypertension). 
This provides a likely explanation for the identified aIAB risk factors as these conditions are 
commonly associated with atrial remodeling. Similarly, these mechanisms provide a 
plausible link between aIAB and AF due to the fact that those with aIAB have the necessary 
substrate to maintain the irregularly irregular rhythm of AF.
It is worth mentioning that blacks were less likely to develop aIAB compared with whites. 
Similar observations have been reported regarding AF risk.16 Although blacks are more 
likely to have an increased number of AF risk factors (e.g., hypertension, smoking), they are 
less likely to have cardiac remodeling. This is supported by data showing that blacks have 
smaller left atrial diameters compared with whites.17 Therefore, the lower aIAB risk among 
blacks would coincide with the decreased prevalence of AF observed in the general 
population.
The current study should be interpreted in the context of several limitations. Incident AF 
cases were ascertained from hospitalization discharge records and death certificates which 
possibly resulted in misclassification. However, these codes have adequate positive 
predictive value for the identification of AF events in ARIC.7 Additionally, paroxysmal AF 
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cases potentially were missed due to the time-dependent nature of such events. Furthermore, 
we included several covariates in our multivariable models that likely influenced the 
development of AF. Similar to other epidemiologic studies, we acknowledge that residual 
confounding remains a possibility.
In conclusion, aIAB is not an uncommon electrocardiographic finding in the ARIC study. 
Several risk factors for aIAB were identified that coincide with conditions associated with 
AF development and provide a plausible link for the observed association between aIAB and 
AF. Our findings also suggest that aIAB is a useful marker to identify persons who are high 
risk for developing AF.
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Figure 1. Cumulative Incidence of Atrial Fibrillation by Advanced Inter-Atrial Block
* Cumulative incidence curves at statistically different (log-rank p<0.0001).
aIAB=advanced inter-atrial block
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Table 1
Characteristics by Prevalent aIAB, Incident aIAB, and No aIAB (N=14,625)*
Advanced Inter-Atrial Block
Characteristics Prevalent (n=69) Incident (n=193) Absent (n=14,363) P-value†
Age, mean ± SD (years) 59 ± 4.9 57 ± 5.5 54 ± 5.7 <0.0001
Male 45 (65%) 121 (63%) 6,377 (44%) <0.0001
Black 23 (33%) 35 (18%) 3,771 (18%) 0.016
Smoking 42 (61%) 122 (63%) 8,383 (58%) 0.37
Diabetes mellitus 19 (28%) 27 (14%) 1,593 (11%) <0.0001
LDL cholesterol, mean ± SD (mg/dl) 143 ± 35 147 ± 38 137 ± 39 0.47
Body mass index, mean ± SD (kg/m2) 30 ± 4.8 29 ± 5.5 28 ± 5.3 <0.0001
Systolic blood pressure, mean ± SD (mm Hg) 132 ± 23 129 ± 19 121 ± 19 <0.0001
Antihypertensive medications 44 (64%) 108 (56%) 4,229 (29%) <0.0001
Coronary heart disease 13 (19%) 18 (9.3%) 658 (4.6%) <0.0001
Heart failure 8 (12%) 18 (9.3%) 630 (4.4%) <0.0001
*
Prevalent aIAB were cases present during visit 1. Incident aIAB cases were identified during visits 2, 3, and 4.
†Statistical significance for categorical data was tested using the chi-square procedure and continuous data was tested using the analysis of variance 
procedure.
aIAB=advanced inter-atrial block; LDL=low-density lipoprotein; SD=standard deviation.
Am J Cardiol. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
O’Neal et al. Page 10
Table 2
Risk Factors for Advanced Inter-Atrial Block (N=14,556)
Characteristics Unadjusted RR (95%CI) P-value Adjusted* RR (95%CI) P-value
Age (per 10-year increase) 2.71 (2.09, 3.54) <0.0001 2.09 (1.57, 2.77) <0.0001
Male 2.08 (1.56, 2.78) <0.0001 2.11 (1.55, 2.87) <0.0001
Black 0.63 (0.43, 0.90) 0.012 0.48 (0.33, 0.69) 0.0001
Smoking 1.22 (0.91, 1.63) 0.18 1.02 (0.76, 1.38) 0.88
Diabetes 1.30 (0.87, 1.94) 0.20 0.75 (0.48, 1.16) 0.19
LDL cholesterol (per 10 mg/dl increase) 1.06 (1.03, 1.09) 0.0001 1.04 (1.01, 1.08) 0.019
Body mass index (per 5 kg/m2 increase) 1.30 (1.19, 1.43) <0.0001 1.31 (1.15, 1.48) <0.0001
Systolic blood pressure (per 10 mm Hg increase) 1.21 (1.15, 1.27) <0.0001 1.14 (1.06, 1.22) 0.0003
Antihypertensive medications 2.99 (2.26, 3.97) <0.0001 2.41 (1.75, 3.30) <0.0001
Coronary heart disease 2.11 (1.31, 3.41) 0.0022 0.91 (0.55, 1.52) 0.73
Heart failure 2.21 (1.37, 3.56) 0.0012 1.21 (0.72, 2.03) 0.47
*Adjusted for age, sex, race, body mass index, systolic blood pressure, smoking, diabetes, LDL cholesterol, coronary heart disease, and heart 
failure.
CI=confidence interval; LDL=low-density lipoprotein; RR=relative risk.
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